Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine aims to shield seniors from pneumococcal disease

NCT ID NCT07712575

Vaccine Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests an experimental vaccine called V132 in healthy adults aged 50 and older. The goal is to see how safe it is and how well it triggers an immune response compared to existing pneumococcal vaccines. Participants will receive one of several formulations of V132 or a comparator vaccine, and researchers will monitor for side effects and measure antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental pneumococcal vaccine called V132
What this could lead to
If successful, V132 could provide better protection against pneumococcal disease for older adults, who are at higher risk.
What could go wrong
This is an early Phase 1 trial focused on safety and immune response, so it is too soon to know if V132 will be effective or have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive) Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination * Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    9 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Anaheim Clinical Trials ( Site 0006)

    RECRUITING

    Anaheim, California, 92801, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)

    RECRUITING

    Springfield, Missouri, 65802, United States

  • QPS-MRA, LLC-Early Phase ( Site 0001)

    RECRUITING

    South Miami, Florida, 33143, United States

  • Remington-Davis, Inc. ( Site 0005)

    RECRUITING

    Columbus, Ohio, 43215, United States

  • Research Centers of America ( Hollywood ) ( Site 0009)

    RECRUITING

    Hollywood, Florida, 33024, United States

  • University of Texas Medical Branch ( Site 0004)

    RECRUITING

    League City, Texas, 77573, United States

  • Velocity Clinical Research Lincoln ( Site 0007)

    RECRUITING

    Lincoln, Nebraska, 68510, United States

  • Velocity Clinical Research, Hallandale Beach ( Site 0003)

    RECRUITING

    Hallandale, Florida, 33009, United States

  • Velocity Clinical Research, Omaha ( Site 0008)

    RECRUITING

    Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.